Cyllene Tx Taps Late-Stage Veterans to Steer Gene Therapy Ambitions

PARIS, FRANCE and NEW YORK, USA – July 23, 2026 – In the high-stakes world of biotechnology, personnel moves are often the most telling indicators of a company's trajectory. Cyllene Therapeutics, a firm developing novel gene therapies for neurological disorders, just sent a powerful signal to the market. By appointing three seasoned female executives to critical leadership and board positions, the company is clearly building a war room for the final, most treacherous stages of drug development.

Cyllene announced the appointment of Alyssa Levin to its Board of Directors as Chair of the Audit Committee, alongside the additions of Clara Cambon-Thiebaud as Vice President of Regulatory Affairs and Céline Breda as Vice President of Chemistry, Manufacturing and Controls (CMC). These are not junior hires; they are strategic acquisitions of talent, each bringing decades of specialized experience precisely when Cyllene needs it most. The company is advancing its lead candidate, EG110A, for neurogenic bladder, and these appointments suggest a deliberate shift from a research-focused entity to one preparing for pivotal trials, regulatory submissions, and potential commercial launch.

"Building a world-class leadership team is essential as we advance Cyllene Tx into its next phase of growth,” said Philippe Cambon, MD, PhD, Co-Founder and Chief Executive Officer. “These appointments strengthen our existing team by adding the late-stage expertise and experience necessary to meet our upcoming corporate goals.”

A Late-Stage Playbook Takes Shape

The profiles of the new appointees read like a checklist for navigating the biotech “valley of death”—the perilous journey from promising clinical data to market approval. Alyssa Levin is a battle-hardened financial strategist. Her resume includes CFO roles at multiple public and private biotechs, where she has raised over $500 million, managed a $240 million public offering for Nkarta, and co-led the $320 million acquisition of ViaCyte by Vertex Pharmaceuticals. Her appointment is a clear move to bolster financial governance and prepare the company for the immense capital demands of late-stage trials, and perhaps, an eventual public offering. "I look forward to working with the Board and management team to help bolster the financial and governance infrastructure a company at this stage needs,” Levin stated, acknowledging the critical juncture Cyllene has reached.

While Levin secures the financial foundations, Clara Cambon-Thiebaud is tasked with navigating the regulatory labyrinth. With over 15 years of global regulatory leadership, she has guided more than 30 development programs from lab to approval. For a company working with a novel gene therapy platform, her expertise is indispensable. Regulatory agencies like the FDA and EMA have exceptionally high bars for gene therapies, demanding rigorous data on safety, efficacy, and manufacturing. Cambon-Thiebaud’s role will be to build the strategic bridge between Cyllene's science and the regulators who hold the keys to the market.

That bridge, however, is built on the foundation of manufacturing, which is where Céline Breda comes in. With a 25-year career dedicated to the CMC of complex biologics and viral vectors, Breda is tackling what is arguably the biggest bottleneck in the gene therapy sector. The challenge of producing viral vectors at scale, with consistent quality and a manageable cost, has grounded many promising therapies. Breda’s deep experience in process development, GMP manufacturing, and technology transfer is a direct investment in de-risking Cyllene’s path to commercialization. "EG110A represents a real opportunity to improve patients' lives, and I'm looking forward to building the CMC strategy that will carry it through the next phase of clinical manufacturing and beyond," Breda commented.

The Science Behind the Strategy

The intense focus on execution is warranted by the novelty of Cyllene's technology. The company's proprietary HERMES platform uses a non-replicating Herpes Simplex Virus-1 (nrHSV-1) as a vector to deliver therapeutic genes. This approach has several key advantages that set it apart. First, HSV-1 vectors have a very large payload capacity, allowing them to carry more complex genetic instructions than smaller vectors like AAVs. Second, they deliver their genetic cargo without integrating into the host's genome, instead existing as a separate episome in the cell nucleus, which mitigates the risk of cancer-causing insertional mutagenesis. Finally, and perhaps most critically, the platform holds the potential for repeat dosing—a major challenge for other viral vectors that trigger a strong immune response.

Cyllene's lead candidate, EG110A, is the first test of this platform in a human sensory neuron-based disease. It targets neurogenic detrusor overactivity (NDO), a severe form of bladder incontinence common in patients with spinal cord injuries, affecting an estimated 2 million people in major markets. The therapy is designed to selectively silence the overactive sensory neurons driving the condition. Early data from the ongoing Phase 1/2 trial have reportedly shown “substantial and sustained reductions in urinary incontinence episodes for at least nine months,” a promising signal in a patient population with few good options.

While Cyllene bills itself as the “global leader” in its niche, it’s important to note the competitive context. Krystal Biotech has already achieved FDA approval for VYJUVEK, its own HSV-1-based therapy for a rare skin disorder, making it the first-ever redosable gene therapy on the market. This success validates the broader HSV-1 vector approach but also sets a high bar for execution. Cyllene’s leadership claim rests on being the first to target sensory neurons for neurological diseases, a distinct and potentially vast field of application.

Fueling the Ascent

Talent and technology alone are not enough; a biotech engine runs on capital. Cyllene recently closed a €33 million ($38 million) Series C financing round, co-led by new investors GordonMD Global Investments and M Ventures, the venture arm of Merck. This infusion, following a €27 million Series B in 2025, provides the necessary runway to advance EG110A into a planned Phase 2b/3 study in 2027 and explore the HERMES platform's potential in other areas like chronic pain and migraine.

The strategic assembly of a late-stage leadership team, backed by fresh capital and a promising technological platform, places Cyllene Therapeutics at a pivotal inflection point. The path forward is fraught with the inherent risks of gene therapy development, from manufacturing hurdles and regulatory scrutiny to the ultimate test of pivotal trial data. However, by proactively recruiting leaders who have successfully navigated these challenges before, Cyllene is not just hoping for success—it is building a deliberate and sophisticated strategy to achieve it.